The FDA on March 26, 2025, approved CABOMETYX® for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic NeuroEndocrine Tumors (pNET) and well-differentiated extra-pancreatic NeuroEndocrine Tumors (epNET). CABOMETYX® is a product of Exelixis, Inc.
Bottom Ad
Advertisement
Subscribe
